Drug intelligence / Profile preview

Agilus

Development stage: Discontinued
Lead developer: Norgine
Administration: Intra-articular Injection

Overview

Agilus is a hyaluronic acid formulation developed for the treatment of mild to moderate ankle osteoarthritis. It is administered via injection to improve joint lubrication and reduce pain, leveraging the natural viscoelastic properties of hyaluronic acid, a key component of synovial fluid.

Beyond the preview

Go deeper on Agilus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agilus.

Explore the full profile